DexCom, Inc. (NASDAQ:DXCM – Get Free Report) Director Mark Foletta sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $85.32, for a total transaction of $170,640.00. Following the completion of the transaction, the director directly owned 48,852 shares in the company, valued at $4,168,052.64. This represents a 3.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
DexCom Trading Down 0.4%
DXCM stock opened at $86.94 on Wednesday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $87.85. The business’s 50-day moving average is $73.74 and its 200 day moving average is $69.43. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The stock has a market cap of $32.81 billion, a price-to-earnings ratio of 34.36, a PEG ratio of 1.48 and a beta of 1.41.
DexCom (NASDAQ:DXCM – Get Free Report) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The business had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business’s revenue was up 13.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.48 earnings per share. On average, sell-side analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current fiscal year.
DexCom News Roundup
- Positive Sentiment: Argus raised its price target to $96 from $86 and maintained a “buy” rating, implying approximately 10% potential upside from the referenced price. Benzinga
- Positive Sentiment: DexCom’s latest quarterly results exceeded expectations, with adjusted earnings of $0.70 per share versus a $0.61 consensus estimate and revenue of $1.31 billion versus $1.29 billion expected. Revenue increased 13.1% year over year, while operating income reportedly grew 49.7%; management also raised its fiscal-year 2026 guidance. DexCom: Still A Cautious Buy Following Earnings
- Positive Sentiment: Growth catalysts include adoption of the G7 glucose-monitoring system, international expansion and the “Road to 100” initiative aimed at broadening diabetes coverage. Margin improvement, share repurchases and a solid balance sheet further support the investment case. DexCom: Still A Cautious Buy Following Earnings
- Positive Sentiment: Technical momentum has improved: DXCM moved above its 20-day moving average and reached a new 52-week high, signaling continued short-term buying interest. DexCom 52-Week High
- Neutral Sentiment: Analyst opinion remains broadly constructive, with another reported price-target increase to $82; however, targets vary significantly. At roughly 34 times earnings, valuation leaves the stock sensitive to any slowdown in growth or weaker guidance. DexCom Price Target Raised
- Negative Sentiment: Director Mark G. Foletta sold a combined 4,000 shares for approximately $330,640 under a pre-arranged Rule 10b5-1 plan. Because the sales were scheduled in advance and he retains a substantial position, the transactions are a limited negative signal rather than clear evidence of declining confidence. SEC Insider Trading Filing
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on DXCM. Mizuho raised their price objective on DexCom from $90.00 to $95.00 and gave the company an “outperform” rating in a report on Friday, July 31st. BTIG Research reaffirmed a “buy” rating and set a $90.00 target price (up from $80.00) on shares of DexCom in a report on Friday. Piper Sandler reiterated an “overweight” rating and issued a $95.00 target price (up from $88.00) on shares of DexCom in a research report on Friday. Truist Financial set a $93.00 price target on shares of DexCom and gave the stock a “buy” rating in a research note on Friday. Finally, Bank of America lowered their price target on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $88.71.
Check Out Our Latest Stock Report on DexCom
Hedge Funds Weigh In On DexCom
Institutional investors have recently added to or reduced their stakes in the stock. Reflection Asset Management purchased a new stake in DexCom in the 4th quarter valued at $25,000. Ascentis Independent Advisors acquired a new stake in shares of DexCom in the 1st quarter worth $25,000. MCF Advisors LLC purchased a new position in shares of DexCom during the 4th quarter worth $32,000. Wellington Grp LLC raised its holdings in shares of DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after acquiring an additional 475 shares during the period. Finally, DV Equities LLC purchased a new position in shares of DexCom during the 4th quarter worth $36,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.
DexCom Company Profile
DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.
Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.
Read More
- Five stocks we like better than DexCom
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
